ClinicalTrials.gov
ClinicalTrials.gov Menu

Varenicline Observational Investigation In The Cessation of Smoking (CHOICES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00669240
Recruitment Status : Completed
First Posted : April 30, 2008
Results First Posted : July 7, 2010
Last Update Posted : July 23, 2015
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.

Condition or disease Intervention/treatment
Smoking Cessation Drug: Varenicline

Detailed Description:
Sampling Method Details: Patients as they come to surgeries for smoking cessation treatment.

Study Type : Observational
Actual Enrollment : 567 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Champix Observational Investigation In The Cessation of Smoking
Study Start Date : November 2007
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
1. Non-interventional
Patients prescribed varenicline in a non interventional manner.
Drug: Varenicline
According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
Other Name: Champix, Chantix, CP-526,555




Primary Outcome Measures :
  1. Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs) [ Time Frame: Baseline through Week 12 or Week 24 ]
    Non-serious AEs are any untoward medical occurrence in a clinical investigation (subject administered a product or medical device) observed or volunteered through 7 days after the last dose of study drug regardless of suspected causal relationship; SAEs are any untoward medical occurrence that results in death; is life-threatening; requires hospitalization or prolongation of hospitalization; results in disability or incapacity; congenital anomaly or birth defect observed or volunteered through 28 days after the last dose of study drug, regardless of suspected causal relationship.


Secondary Outcome Measures :
  1. Number of Participants Whose Smoking Status Was Known at the End of 12 Weeks [ Time Frame: Week 12 ]
    Number of participants who were determined to be a responder or a non-responder at the specified time point. (Responders are participants who answered "no" to both of the following 2 questions, and non-responders are participants who answered "yes" to at least 1 of the following 2 questions, on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?)

  2. Number of Participants in Belgium Whose Smoking Status Was Known at the End of 12 Weeks and 24 Weeks [ Time Frame: Week 12 and Week 24 ]
    Number of participants in Belgium who were determined to be a responder or a non-responder at the specified time point. (Responders are participants who answered "no" to both of the following 2 questions, and non-responders are participants who answered "yes" to at least 1 of the following 2 questions, on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?)

  3. Number of Treatment Responders at Week 12 [ Time Frame: Week 12 ]
    Responders are participants who answered "no" to both of the following 2 questions on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?

  4. Number of Treatment Responders in Belgium at Week 12 and at Week 24 [ Time Frame: Week 12 and Week 24 ]
    Responders are participants who answered "no" to both of the following 2 questions on the Nicotine Use Inventory (NUI): 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days?

  5. Number of Participants With Smoking Cessation Assessments at Weekly Intervals From Week 3 Through Week 11 [ Time Frame: Weeks 3, 4, 5, 6, 7, 8, 9, 10, and 11 ]
    Assessment of smoking cessation (ie, not a single puff) in previous 7 days, at time points of routine review of patients per local clinical practice.

  6. Number of Treatment Responders at Weekly Intervals From Week 3 Through Week 11 [ Time Frame: Weeks 3, 4, 5, 6, 7, 8, 9, 10, and 11 ]
    Responders are participants who answered "no" to the following 2 questions: 1) Has the subject smoked any cigarettes (even a puff) in the last 7 days? 2) Has the subject used any other tobacco products (for example, pipe, cigars, snuff, chew) in the last 7 days? Assessment conducted at specified time points only when usual for the local clinical practice.

  7. Number of Participants for Whom a Maintenance Period of Varenicline Was Prescribed at the End of Week 12 [ Time Frame: Week 12 ]
    A maintenance period was an additional period of varenicline treatment that could be prescribed at Week 12 by the attending primary care physician in routine clinical practice

  8. Number of Participants Who Received Varenicline, by Duration of Treatment in Days [ Time Frame: Baseline through Week 12 or Week 24 ]
  9. Number of Participants Who Registered With LifeREWARDS On-line Behavioral Support Program [ Time Frame: Week 12 ]
    Number of participants who answered 'yes' to the question "Did you register with LifeREWARDS?" (LifeREWARDS not available in Greece.)

  10. Minnesota Nicotine Withdrawal Scale (MNWS) Subscale Scores for Participants in Belgium [ Time Frame: Week 7 and Week 13 or 14 (Week 13/14) ]
    Self-administered rating of intensity of nicotine withdrawal symptoms over past 24 hours; consists of 9 questions (urge to smoke, depressed mood, irritability, anxiety, difficulty concentrating, restlessness, increased appetite, difficulty going to sleep, difficulty staying asleep), each rated 0-4 (0=not at all, 1=slight, 2=moderate, 3=quite a bit, 4=extreme). Subscales: Negative affect domain (average of items 2-5); Insomnia domain (average of items 8 and 9); Urge to smoke (item 1); Restlessness (item 6); Increased appetite (item 7). Range 0-4 (higher score=greater intensity of symptoms)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes. The patients must be willing to make an attempt to stop smoking.

All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.

Criteria

Inclusion Criteria:

  • The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.
  • The patients must be willing to make an attempt to stop smoking.

Exclusion Criteria:

  • All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00669240


  Show 52 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer